[A24-77] Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V
Last updated 04.11.2024
Project no.:
A24-77
Commission:
Commission awarded on 30.07.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with advanced non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations
Hint of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-77
| Project no. | Title | Status |
|---|---|---|
| A24-72 | Osimertinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-86 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-45 | Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-20 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-14 | Osimertinib - Benefit assessment according to §35a Social Code Book V | Commission completed |